Our aim is to provide the reader with an easy-to-read update that can be used to drive the clinician’s therapeutical approach to these patients after the molecular diagnosis (Diabetes Therapy)
Diabetes News
Tag: MODY
Update on clinical screening of maturity-onset diabetes of the young (MODY)
The selection of diabetic patients for genetic testing is an ongoing challenge. Metabolic profiling, diabetes onset age, pancreatic antibodies, and C-peptide seem to be useful tools to better select patients for genetic testing (Diabetology & Metabolic Syndrome)
Successful maintenance on sulfonylurea therapy and low diabetes complication rates in a HNF1A–MODY cohort
This study demonstrates that the majority of patients with HNF1A–MODY can be maintained successfully on sulfonylurea therapy with good glycaemic control. We note a significantly lower rate of micro- and macrovascular complications than reported previously (Diabetic Medicine)
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young
The pathophysiology of HNF1A-diabetes includes exaggerated postprandial glucagon responses and increased fasting DPP-4 enzymatic activity, but normal postprandial incretin responses in both patients with GCK-diabetes and HNF1A-diabetes (European Journal of Endocrinology)
Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents
We showed that the UCPCR and fasting C-peptide levels in children and adolescents can distinguish patients with MODY from patients with T1DM with high specificity and sensitivity (Hormone Research in Paediatrics)
Glycosmedia is also available as an App: